Weshalb die Cara Therapeutics-Aktie
ein D-Rating hat,
erfahren Sie im Performance-Check
vom 21. März 2026 Info.
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2025 | 1,21 | 3,07 | 153,72% |
| 2 | 2015 | 289,94 | 523,04 | 80,40% |
| 3 | 2019 | 380,88 | 524,88 | 37,81% |
| 4 | 2017 | 316,51 | 389,09 | 22,93% |
| 5 | 2018 | 389,09 | 380,88 | -2,11% |
| 6 | 2022 | 388,80 | 363,96 | -6,39% |
| 7 | 2021 | 441,18 | 388,80 | -11,87% |
| 8 | 2020 | 524,88 | 441,18 | -15,95% |
| 9 | 2026 | 3,07 | 2,56 | -16,61% |
| 10 | 2016 | 523,04 | 316,51 | -39,49% |
| 11 | 2023 | 363,96 | 23,54 | -93,53% |
| 12 | 2024 | 23,54 | 1,21 | -94,86% |
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2024 | 23,54 | 1,21 | -94,86% |
| 2 | 2023 | 363,96 | 23,54 | -93,53% |
| 3 | 2016 | 523,04 | 316,51 | -39,49% |
| 4 | 2026 | 3,07 | 2,56 | -16,61% |
| 5 | 2020 | 524,88 | 441,18 | -15,95% |
| 6 | 2021 | 441,18 | 388,80 | -11,87% |
| 7 | 2022 | 388,80 | 363,96 | -6,39% |
| 8 | 2018 | 389,09 | 380,88 | -2,11% |
| 9 | 2017 | 316,51 | 389,09 | 22,93% |
| 10 | 2019 | 380,88 | 524,88 | 37,81% |
| 11 | 2015 | 289,94 | 523,04 | 80,40% |
| 12 | 2025 | 1,21 | 3,07 | 153,72% |